{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:59:48Z","timestamp":1791809988102,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajt.2025.12.290","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:01:45Z","timestamp":1770127305000},"page":"797-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-4680","authenticated-orcid":false,"given":"Flavio","family":"Vincenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2505-6372","authenticated-orcid":false,"given":"Jun","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-507X","authenticated-orcid":false,"given":"David","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-5517","authenticated-orcid":false,"given":"Jim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3696-2960","authenticated-orcid":false,"given":"Wenjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9921-9690","authenticated-orcid":false,"given":"Todd M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-5962","authenticated-orcid":false,"given":"Allan D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajt.2025.12.290_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ackd.2016.07.001","article-title":"Current status of kidney transplant outcomes: dying to survive","volume":"23","author":"Wang","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"10.1016\/j.ajt.2025.12.290_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1432-2277.2008.00728.x","article-title":"Minimization of steroids in kidney transplantation","volume":"22","author":"Matas","year":"2009","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.ajt.2025.12.290_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2025.12.290_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","article-title":"Incidence and long-term cost of steroid-related side effects after renal transplantation","volume":"33","author":"Veenstra","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.ajt.2025.12.290_bib5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/ckj\/sfac017","article-title":"Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation","volume":"15","author":"Gandolfini","year":"2022","journal-title":"Clin Kidney J"},{"issue":"6581","key":"10.1016\/j.ajt.2025.12.290_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/381434a0","article-title":"Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways","volume":"381","author":"Larsen","year":"1996","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ajt.2025.12.290_bib7","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1073\/pnas.94.16.8789","article-title":"CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates","volume":"94","author":"Kirk","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ajt.2025.12.290_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-6143.2012.04342.x","article-title":"Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion","volume":"13","author":"Lo","year":"2013","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2025.12.290_bib9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2025.12.290_bib10","series-title":"Package insert","year":"2014"},{"issue":"12","key":"10.1016\/j.ajt.2025.12.290_bib11","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.12.290_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-6143.2002.20406.x","article-title":"The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells","volume":"2","author":"Nathan","year":"2002","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2025.12.290_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"issue":"711","key":"10.1016\/j.ajt.2025.12.290_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6376","article-title":"The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates","volume":"15","author":"Anwar","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajt.2025.12.290_bib15","unstructured":"Safety and efficacy of tegoprubart in patients undergoing kidney transplantation. ClinicalTrials.gov identifier: NCT05983770. Updated October 19, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05983770"},{"issue":"suppl 3","key":"10.1016\/j.ajt.2025.12.290_bib16","article-title":"CNI-free therapy with iscalimab (anti-CD40 mAb) preserves allograft histology compared to standard of care after kidney transplantation","volume":"19","author":"Farkash","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2025.12.290_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/13543784.2022.2130751","article-title":"Investigational drugs for the treatment of kidney transplant rejection","volume":"31","author":"van Vugt","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.ajt.2025.12.290_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2025.12.290_bib19","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0041-1345(99)00100-1","article-title":"Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand","volume":"31","author":"Knechtle","year":"1999","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.ajt.2025.12.290_bib20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-200210150-00006","article-title":"Anti-CD40 therapy extends renal allograft survival in rhesus macaques","volume":"74","author":"Pearson","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.ajt.2025.12.290_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.TP.0000054835.58014.C2","article-title":"Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates","volume":"75","author":"Haanstra","year":"2003","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2025.12.290_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-019-01226-6","article-title":"Costimulation blockade in kidney transplant recipients","volume":"80","author":"van der Zwan","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ajt.2025.12.290_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2025.12.290_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"suppl 2","key":"10.1016\/j.ajt.2025.12.290_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2017-eular.3468","article-title":"SAT0249 Safety, pharmacokinetics, pharmacodynamics, and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study","volume":"76","author":"Albulescu","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"489","key":"10.1016\/j.ajt.2025.12.290_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ajt.2025.12.290_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2025.12.290_bib28","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/TP.0000000000004570","article-title":"Failure of costimulatory blockade-induced regulatory T cells to sustain long-term survival of high ischemic allografts","volume":"107","author":"Kohei","year":"2023","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.ajt.2025.12.290_bib29","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2025.12.290_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2025.12.290_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2025.12.290_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861471","article-title":"The inhibition of CD40\/CD154 costimulatory signaling in the prevention of renal transplant rejection in nonhuman primates: a systematic review and meta analysis","volume":"13","author":"Perrin","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ajt.2025.12.290_bib33","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.ajt.2024.03.033","article-title":"Differential induction of donor-reactive Foxp3+ regulatory T cell via blockade of CD154 vs CD40","volume":"24","author":"Liu","year":"2024","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2025.12.290_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204219","article-title":"Medication adherence in renal transplant recipients: a latent variable model of psychosocial and neurocognitive predictors","volume":"13","author":"Paterson","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ajt.2025.12.290_bib35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.TP.0000110408.83054.88","article-title":"Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ajt.2025.12.290_bib36","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ajt.2025.07.2474","article-title":"Therapeutic needs in solid organ transplant recipients: the American Society of Transplantation patient survey","volume":"25","author":"Taber","year":"2025","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2025.12.290_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/TP.0b013e3182543950","article-title":"De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy","volume":"94","author":"Willicombe","year":"2012","journal-title":"Transplantation"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613526000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:28:11Z","timestamp":1777620491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613526000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1600613526000031"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.12.290","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.12.290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}